Pfizer, Hydra Ink Deal To Develop Novel Ion Channel Antagonists For Pain
Collaboration, valued at $195 million, will focus on transient receptor potential ion channel antagonists for pain.
Collaboration, valued at $195 million, will focus on transient receptor potential ion channel antagonists for pain.